

<b>NCT ID</b>	NCT06176885
<b>Title</b>	Efficacy and Safety of Combined With Immunotherapy After Induction Therapy With Chemotherapy and Targeted Therapy in the First-line Treatment of Microsatellite Stable (MSS) Initially Unresectable Metastatic Colorectal Cancer
<b>Phase</b>	Phase 2
<b>Date Added</b>	2023-12-20
<b>Location</b>	China
<b>Prior IO Allowed</b>	No
<b>CRC-directed</b>	Yes
<b>Status</b>	Recruiting
<b>Drugs</b>	Camrelizumab
<b>Tags</b>	MSS/ MMRp
<b>NCT ID</b>	NCT02537418
<b>Title</b>	Durvalumab With or Without Tremelimumab in Advanced Incurable Solid Malignancies Given With or Without Standard Chemotherapy Regimens
<b>Phase</b>	Phase 1
<b>Date Added</b>	2015-09-01
<b>Location</b>	Canada
<b>Prior IO Allowed</b>	Yes
<b>CRC-directed</b>	No
<b>Status</b>	Active, not recruiting
<b>Drugs</b>	durvalumab, Tremelimumab, Imfinzi
<b>Tags</b>	MSS/ MMRp
<b>NCT ID</b>	NCT02888743
<b>Title</b>	Durvalumab and Tremelimumab With or Without High or Low-Dose Radiation Therapy in Treating Patients With Metastatic Colorectal or Non-small Cell Lung Cancer
<b>Phase</b>	Phase 2
<b>Date Added</b>	2016-09-05
<b>Location</b>	Arizona, United States California, United States Connecticut, United States Florida, United States Georgia, United States Kentucky, United States Maryland, United States Massachusetts, United States Michigan, United States Minnesota, United States Missouri, United States New Jersey, United States North Carolina, United States Ohio, United States Pennsylvania, United States Tennessee, United States Virginia, United States Wisconsin, United States Canada
<b>Prior IO Allowed</b>	Yes
<b>CRC-directed</b>	Yes
<b>Status</b>	Active, not recruiting
<b>Drugs</b>	durvalumab, Tremelimumab
<b>Tags</b>	MSS/ MMRp
<b>NCT ID</b>	NCT03911557
<b>Title</b>	Durvalumab and Tremelimumab Combination in Somatically Hypermutated Recurrent Solid Tumors

<b>Phase</b>	Phase 2
<b>Date Added</b>	2019-04-11
<b>Location</b>	Kentucky, United States
<b>Prior IO Allowed</b>	No
<b>CRC-directed</b>	No
<b>Status</b>	Active, not recruiting
<b>Drugs</b>	Durvalumab and Tremelimumab
<b>Tags</b>	MSS/ MMRp
<b>NCT ID</b>	NCT05479812
<b>Title</b>	Dose Escalation Study of WTX-124 as Monotherapy and in Combination With Pembrolizumab (Pembro) in Patients With Selected Advanced or Metastatic Solid Tumors
<b>Phase</b>	Phase 1
<b>Date Added</b>	2022-07-29
<b>Location</b>	Arizona, United States Florida, United States Georgia, United States Illinois, United States Indiana, United States New Jersey, United States New York, United States Oregon, United States Texas, United States
<b>Prior IO Allowed</b>	Yes
<b>CRC-directed</b>	No
<b>Status</b>	Recruiting
<b>Drugs</b>	Pembrolizumab, WTX-124
<b>Tags</b>	MSI-H/ MMRd
<b>NCT ID</b>	NCT03310008
<b>Title</b>	Dose Escalation and Dose Expansion Phase I Study to Assess the Safety and Clinical Activity of Multiple Doses of NKR-2 Administered Concurrently With FOLFOX in Colorectal Cancer With Potentially Resectable Liver Metastases
<b>Phase</b>	Phase 1
<b>Date Added</b>	2017-10-16
<b>Location</b>	Belgium
<b>Prior IO Allowed</b>	No
<b>CRC-directed</b>	Yes
<b>Status</b>	Active, not recruiting
<b>Drugs</b>	NKR-2 cells
<b>Tags</b>	MSS/ MMRp
<b>NCT ID</b>	NCT05493683
<b>Title</b>	Disitamab Vedotin Combined With Tislelizumab in Advanced HER2 Positive Colorectal Cancer
<b>Phase</b>	Phase 2
<b>Date Added</b>	2022-08-09
<b>Location</b>	China,China,China,China,China,China
<b>Prior IO Allowed</b>	Yes
<b>CRC-directed</b>	Yes
<b>Status</b>	Recruiting
<b>Drugs</b>	Disitamab vedotin, Tislelizumab
<b>Tags</b>	MSI-H/ MMRd, MSS/ MMRp
<b>NCT ID</b>	NCT05770102

<b>Title</b>	DETERMINE Trial Treatment Arm 2: Atezolizumab in Adult, Teenage/Young Adults and Paediatric Patients With Cancers With High Tumour Mutational Burden (TMB) or Microsatellite Instability-high (MSI-high) or Proven Constitutional Mismatch Repair Deficiency (CMMRD) Disposition
<b>Phase</b>	Phase 2
<b>Date Added</b>	2023-03-15
<b>Location</b>	United Kingdom
<b>Prior IO Allowed</b>	No
<b>CRC-directed</b>	No
<b>Status</b>	Recruiting
<b>Drugs</b>	Atezolizumab
<b>Tags</b>	MSI-H/ MMRd
<b>NCT ID</b>	NCT03668431
<b>Title</b>	Dabrafenib + Trametinib + PDR001 In Colorectal Cancer
<b>Phase</b>	Phase 2
<b>Date Added</b>	2018-09-12
<b>Location</b>	Massachusetts, United States
<b>Prior IO Allowed</b>	Yes
<b>CRC-directed</b>	Yes
<b>Status</b>	Recruiting
<b>Drugs</b>	Dabrafenib, PDR001, Trametinib, Mekinist, Tafinlar
<b>Tags</b>	MSI-H/ MMRd, MSS/ MMRp
<b>NCT ID</b>	NCT03566355
<b>Title</b>	Curative Proton Beam Therapy for Patients With Lung Metastasis of Colorectal Cancer
<b>Phase</b>	Not Applicable
<b>Date Added</b>	2018-06-25
<b>Location</b>	Korea, Republic of
<b>Prior IO Allowed</b>	Yes
<b>CRC-directed</b>	Yes
<b>Status</b>	Recruiting
<b>Drugs</b>	
<b>Tags</b>	MSI-H/ MMRd, MSS/ MMRp